NEW YORK -- Biotechnology company ImClone Systems Inc. said yesterday that it was considering a buyout offer worth $70 per share from an unidentified large pharmaceutical company, and rejected a $60-per-share bid from Bristol-Myers Squibb Co.

ImClone said Chairman Carl Icahn had been in talks with the chief executive of the pharmaceutical company that made the new offer. ImClone's board will allow the potential buyer two weeks to do due diligence. ImClone said it had not decided if the offer is adequate.

The new offer would be a premium of 10 percent to ImClone's closing price yesterday of $63.65. In morning trading, ImClone stock jumped $4.85, or 7.6 percent, to $68.50.

ImClone also formally rejected the $4.5 billion offer made July 31 by Bristol-Myers, its partner in selling the colon- and head-and-neck cancer drug Erbitux. ImClone said in August that the Bristol-Myers offer undervalued the company, but it did not officially reject the bid. Billionaire investor Icahn was said to be opposed to the Bristol-Myers offer.

Advertise with us

The offer was a 29.2 percent premium to ImClone's July 30 closing price, but the stock has traded above $60 since that time, indicating investors expected a higher sale price.

Bristol-Myers Squibb declined to comment.